Editas Medicine (EDIT), Celgene Corp. (CELG) Update Collaboration Agreement to Develop/Commercialize Autologous & Allogeneic T Cell Medicines

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. MSFT
10. IBM

Go back to Editas Medicine (EDIT), Celgene Corp. (CELG) Update Collaboration Agreement to Develop/Commercialize Autologous & Allogeneic T Cell Medicines

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

November 12, 2019 7:00 AM EST

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells

Editas Medicine to receive a $70 million payment and may be eligible for future milestone and royalty payments

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a... More